p16 and MIB1 improve the sensitivity and specificity of the diagnosis of high grade squamous intraepithelial lesions: Methodological issues in a report of 447 biopsies with consensus diagnosis and HPV HCII testing

Gynecologic Oncology

Volumn 107, Issue 1 SUPPL., 2007, Pages

  Van Niekerk, Dirk ^a,b,d   Guillaud, Martial ^a,d   Matisic, Jasenka ^a,b,d   Benedet, John L ^a,d   Freeberg, J Adrian ^d,e   Follen, Michele ^c,d,e   MacAulay, Calum ^a,d  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c Rice University   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; PROTEIN P16; TUMOR MARKER;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER RISK; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN TISSUE; LABORATORY TEST; MAJOR CLINICAL STUDY; METHODOLOGY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; STAINING; UTERINE CERVIX CARCINOMA IN SITU; UTERUS BIOPSY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN-PROTEIN LIGASES; UTERINE CERVICAL NEOPLASMS;

EID: 34748904273     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.07.064     Document Type: Article

References (19)

1. Malpica A., Matisic J.P., Niekirk D.V., Crum C.P., Staerkel G.A., Yamal J.M., et al. Kappa statistics to measure interrater and intrarater agreement for 1790 cervical biopsy specimens among twelve pathologists: qualitative histopathologic analysis and methodologic issues. Gynecol Oncol 99 (2005) S38-S52
2. Landis J.R., and Koch G.G. The measurement of observer agreement for categorical data. Biometrics 33 (1977) 159-174
3. Stoler M.H., and Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. Jama 285 (2001) 1500-1505
4. Wang S.S., Trunk M., Schiffman M., Herrero R., Sherman M.E., Burk R.D., et al. Validation of p16INK4a as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica. Cancer Epidemiol Biomark Prev 13 (2004) 1355-1360
5. Negri G., Vittadello F., Romano F., Kasal A., Rivasi F., Girlando S., Mian C., et al. p16INK4a expression and progression risk of low-grade intraepithelial neoplasia of the cervix uteri. Virchows Arch 445 (2004) 616-620
6. Sano T., Oyama T., Kashiwabara K., Fukuda T., and Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 153 (1998) 1741-1748
7. Wang J.L., Zheng B.Y., Li X.D., Nokelainen K., Angstrom T., Lindstrom M.S., et al. p16INK4A and p14ARF expression pattern by immunohistochemistry in human papillomavirus-related cervical neoplasia. Mod Path 18 (2005) 629-637
8. Zhang Q., Kuhn L., Denny L.A., De Souza M., Taylor S., and Wright Jr. T.C. Impact of utilizing p16INK4A immunohistochemistry on estimated performance of three cervical cancer screening tests. Int J Cancer 120 (2007) 351-356
9. Bulten J., van der Laak J.A., Gemmink J.H., Pahlplatz M.M., de Wilde P.C., and Hanselaar A.G. MIB1, a promising marker for the classification of cervical intraepithelial neoplasia. J Pathol 178 (1996) 268-273
10. Kruse A.J., Baak J.P., de Bruin P.C., Jiwa M., Snijders W.P., Boodt P.J., et al. Ki-67 immunoquantitation in cervical intraepithelial neoplasia (CIN): a sensitive marker for grading. J Pathol 193 (2001) 48-54
11. Popiolek D., Ventura K., and Mittal K. Distinction of low-grade squamous intraepithelial lesions from high-grade squamous intraepithelial lesions based on quantitative analysis of proliferative activity. Oncol Rep 11 (2004) 687-691
12. Follen M., and Schottenfeld D. Surrogate endpoint biomarkers and their modulation in cervical chemoprevention trials. Cancer 91 (2001) 1758-1776
13. Keating J.T., Cviko A., Riethdorf S., Riethdorf L., Quade B.J., and Sun D. Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol 25 (2001) 884-891
14. Walts A.E., Lechago J., and Bose S. P16 and Ki67 immunostaining is a useful adjunct in the assessment of biopsies for HPV-associated anal intraepithelial neoplasia. Am J Surg Pathol 30 (2006) 795-801
15. Wayne S., and Robinson R.A. Upper aerodigestive tract squamous dysplasia: correlation with p16, p53, pRb, and Ki-67 expression. Arch Pathol Lab Med 130 (2006) 1309-1314
16. Guillaud M., Benedet J.L., Cantor S.B., Staerkel G., Follen M., and MacAulay C. DNA ploidy compared with human papilloma virus testing (Hybrid Capture II) and conventional cervical cytology as a primary screening test for cervical high-grade lesions and cancer in 1555 patients with biopsy confirmation. Cancer 107 (2006) 309-318
17. Guillaud M., Cox D., Malpica A., Staerkel G., Matisic J., Van Niekirk D., et al. Quantitative histopathological analysis of cervical intra-epithelial neoplasia sections: methodological issues. Cell Oncol 26 (2004) 31-43
18. Guillaud, M., Lam, N., Lam, S. MacAulay, C. in International Conference on Applied Genomics 719th ESACP/16th ESDQP Meeting.
19. Guillaud M., Matthews J.B., Harrison A., MacAulay C., and Skov K. A novel image cytometric method for quantitation of immunohistochemical staining of cytoplasmic antigens. Anal Cell Pathol 14 (1997) 87-99